CSAM Health Group AS (CSAMF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CSAM Health Group AS (CSAMF) trades at $4.82 with AI Score 52/100 (Grade B). CSAM Health Group AS provides e-health solutions internationally, focusing on radiology, maternity care, and emergency response systems. Market cap: $98.80M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CSAMF: CSAMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSAMF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CSAMF: 2/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →CSAM Health Group AS (CSAMF) Healthcare & Pipeline Overview
CSAM Health Group AS delivers specialized e-health solutions, including systems for radiology, maternity care, and emergency response, primarily in Norway and internationally. With a $98.80M market cap and a high P/E ratio, CSAM focuses on niche healthcare IT markets, demonstrating a commitment to innovation within the healthcare sector.
What Is the Investment Thesis for CSAMF?
CSAM Health Group AS presents a focused investment opportunity within the e-health sector, driven by its specialized solutions in radiology, maternity care, and emergency response systems. With a market capitalization of $98.80M and a gross margin of 74.5%, CSAM demonstrates strong profitability in its niche markets. The company's growth is predicated on expanding its international presence and continued innovation in its product offerings. However, the high P/E ratio of 127.22 suggests a premium valuation, requiring careful consideration of future earnings growth. Key catalysts include the increasing adoption of e-health solutions globally and the potential for strategic partnerships. Potential risks include competition from larger healthcare IT providers and the challenges of navigating regulatory landscapes in different countries. The company's beta of 0.58 indicates lower volatility compared to the market, which may appeal to risk-averse investors.
Based on FMP financials and quantitative analysis
CSAMF Key Highlights
- Market capitalization of $98.80M, reflecting the company's valuation in the e-health market.
- P/E ratio of 127.22, indicating a premium valuation based on current earnings.
- Gross margin of 74.5%, showcasing strong profitability in its specialized e-health solutions.
- Profit margin of 1.3%, reflecting the net profitability after all expenses.
- Beta of 0.58, suggesting lower volatility compared to the broader market.
Who Are CSAMF's Competitors?
CSAMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADOIF Adocia S.A. | $8.87 | +0.00% | $103.66M | 52 |
| CKMTF Carmat S.A. | $12.75 | -50.96% | $85.19M | 61 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| COLRF China Medical & HealthCare Group Limited | $0.08 | +0.00% | $123.01M | 48 |
| EPRXF Eupraxia Pharmaceuticals Inc. | $3.04 | -6.17% | $108.29M | 44 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSAMF's Key Strengths?
- Specialized expertise in niche areas like radiology and maternity care.
- Integrated suite of e-health solutions.
- Strong customer relationships and recurring revenue.
- Compliance with healthcare regulations and standards.
What Are CSAMF's Weaknesses?
- Relatively small market capitalization compared to larger competitors.
- High P/E ratio indicating a premium valuation.
- Limited geographic presence, primarily in Norway and international markets.
- Dependence on specific niche markets, making it vulnerable to changes in those markets.
What Could Drive CSAMF Stock Higher?
- Potential partnerships with other healthcare IT providers to expand product offerings.
- Increasing adoption of telemedicine and remote patient monitoring driving demand for CSAM's solutions.
- Expansion into new geographic markets with growing healthcare infrastructure.
- Development and launch of new data analytics tools to provide insights to healthcare providers.
- Continued innovation in e-health solutions to address emerging needs in the healthcare industry.
What Are the Key Risks for CSAMF?
- Financial-distress signal — its Altman Z-Score of 1.14 sits in the distress zone (elevated bankruptcy risk).
- Competition from larger healthcare IT providers with broader product offerings.
- Changes in healthcare regulations and standards.
- Economic downturns affecting healthcare spending.
- Cybersecurity threats and data breaches.
- Limited financial disclosure due to OTC listing.
What Are the Growth Opportunities for CSAMF?
- Expansion into New Geographic Markets: CSAM has the opportunity to expand its e-health solutions into new geographic markets, particularly in regions with growing healthcare infrastructure and increasing adoption of digital health technologies. This expansion could significantly increase revenue and market share, leveraging the company's established expertise in specialized areas like radiology and maternity care. The global e-health market is projected to grow substantially, offering a favorable environment for CSAM's international expansion efforts, with a potential timeline of 3-5 years.
- Product Innovation and Development: CSAM can drive growth by continuously innovating and developing new e-health solutions that address emerging needs in the healthcare industry. This includes leveraging technologies such as artificial intelligence and machine learning to enhance the capabilities of its existing products and create new offerings. Focus on remote patient monitoring and telehealth solutions can capitalize on the growing trend towards virtual care, with ongoing product development efforts.
- Strategic Partnerships and Acquisitions: CSAM can pursue strategic partnerships and acquisitions to expand its product portfolio, enter new markets, and gain access to new technologies. Collaborating with other healthcare IT providers or acquiring companies with complementary solutions can accelerate growth and strengthen CSAM's competitive position. Target companies specializing in niche healthcare IT solutions, with potential partnerships and acquisitions within the next 2-3 years.
- Increased Adoption of Telemedicine: The increasing adoption of telemedicine and remote patient monitoring presents a significant growth opportunity for CSAM. The company's existing solutions, such as CSAM Infobroker and CSAM S7, can be leveraged to support virtual care delivery models and improve access to healthcare services. Focus on integrating these solutions with other healthcare systems and expanding their functionality to meet the evolving needs of telemedicine providers, with ongoing integration and expansion efforts.
- Focus on Data Analytics and Insights: CSAM can leverage its extensive data assets to provide valuable insights and analytics to healthcare providers. By analyzing patient data and clinical outcomes, CSAM can help providers improve care quality, reduce costs, and optimize operational efficiency. Developing advanced analytics tools and dashboards can create new revenue streams and differentiate CSAM from its competitors, with a focus on developing and launching new analytics tools within the next 1-2 years.
What Opportunities Does CSAMF Have?
- Expansion into new geographic markets with growing healthcare infrastructure.
- Product innovation and development to address emerging needs in the healthcare industry.
- Strategic partnerships and acquisitions to expand product portfolio and market reach.
- Increased adoption of telemedicine and remote patient monitoring.
What Threats Does CSAMF Face?
- Competition from larger healthcare IT providers with broader product offerings.
- Changes in healthcare regulations and standards.
- Economic downturns affecting healthcare spending.
- Cybersecurity threats and data breaches.
What Are CSAMF's Competitive Advantages?
- Specialized Solutions: Focuses on niche areas like radiology and maternity care, creating a competitive advantage through specialized expertise.
- Integrated Systems: Offers a suite of integrated solutions that work together seamlessly, providing a comprehensive e-health platform.
- Long-Term Customer Relationships: Builds long-term relationships with its customers through ongoing support and maintenance services.
- Regulatory Compliance: Ensures its solutions comply with relevant healthcare regulations and standards, providing a trusted and reliable platform.
What Does CSAMF Do?
Founded in 1999 and headquartered in Oslo, Norway, CSAM Health Group AS specializes in providing e-health solutions designed to improve healthcare efficiency and patient outcomes. The company's comprehensive suite of products includes systems for teleradiology (CSAM Arcidis), radiology data handling (CSAM DICOM Server), and secure patient data transfer (CSAM HelseMail). CSAM also offers telemedicine solutions like CSAM Infobroker, which facilitates resource and knowledge sharing among clinicians. Their portfolio extends to platforms for self-care and health counseling (CSAM S7), web-based user interfaces (CSAM Web Client), and central archives for clinical data management (CSAM XDS). CSAM's solutions cater to various healthcare needs, including cardiology with tools like CSAM Cardio, and maternity care with systems like CSAM Partus and CSAM Natus. They also provide emergency medical information systems (CSAM AMIS) and oncology management solutions (CSAM Cytodose). The company's geographic focus is primarily in Norway and other international markets, where they aim to establish themselves as a key player in specialized healthcare IT solutions. CSAM competes with other healthcare IT providers by offering niche solutions tailored to specific clinical needs, such as maternity and emergency care, differentiating themselves from broader healthcare IT platforms.
What Products and Services Does CSAMF Offer?
- Provides e-health solutions for radiology, including teleradiology and data handling.
- Offers systems for maternity care, such as maternity information and care systems.
- Develops emergency medical information systems for assessing and prioritizing patients.
- Provides solutions for secure transfer of confidential patient data.
- Offers platforms for self-care and health counseling.
- Develops oncology management solutions and laboratory information management systems.
- Provides web-based user interfaces and connectivity solutions for accessing CSAM applications.
How Does CSAMF Make Money?
- Software Licensing: Generates revenue through licensing its e-health software solutions to hospitals, clinics, and other healthcare providers.
- Subscription Services: Offers subscription-based access to its cloud-based services and platforms.
- Maintenance and Support: Provides ongoing maintenance and support services to its customers, generating recurring revenue.
- Professional Services: Offers consulting, implementation, and training services to help customers deploy and use its solutions effectively.
What Industry Does CSAMF Operate In?
CSAM Health Group AS operates within the healthcare information technology (IT) sector, which is experiencing significant growth due to the increasing adoption of digital health solutions. The global healthcare IT market is projected to reach hundreds of billions of dollars by 2026, driven by factors such as the need for improved healthcare efficiency, better patient outcomes, and regulatory mandates for electronic health records. CSAM competes with companies like ADOIF (Allscripts Healthcare Solutions), CKMTF (Cerner Corporation), CNVCF (Teladoc Health), COLRF (NextGen Healthcare), and EPRXF (athenahealth), focusing on specialized areas like radiology and maternity care to differentiate itself in the competitive landscape.
Who Are CSAMF's Key Customers?
- Hospitals: Provides e-health solutions to hospitals for managing radiology, maternity care, and emergency medical information.
- Clinics: Offers its software and services to clinics for improving patient care and operational efficiency.
- Healthcare Providers: Caters to individual healthcare providers who need secure data transfer and telemedicine solutions.
- Government Healthcare Organizations: Partners with government healthcare organizations to implement national e-health initiatives.
Company Profile
CSAM Health Group AS operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Oslo, NO. The company is led by CEO Sverre Flatby. CSAMF has traded publicly since 2022.
F-Score 4/9Financial Health
CSAM Health Group AS's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.14 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -4.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.67 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -4.5%, the inverse of the P/E and a quick read on earnings relative to price.
CSAMF Valuation & Market Position
With a $98.80M market cap, CSAM Health Group AS sits in the micro-cap segment of the market. Relative to its peer group, CSAMF's quantitative score of 52/100 is roughly in line with the peer average of 54/100.
FY2026 estForward Outlook
Wall Street analysts project CSAM Health Group AS revenue of about $458.7M for fiscal 2026, with EPS near $1.96.
CSAMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying activity suggests strong confidence in the company's future prospects. This aligns with the general feeling that healthcare tech is a growing sector.
- The community sentiment seems optimistic, with many users highlighting the potential for growth in their specific healthcare niche. It's a 'rising tide lifts all boats' mentality.
- Positive market perception around digital health solutions could benefit CSAM Health Group. Think of it like the early days of cloud computing – everyone wants in.
- The overall feeling is that CSAM Health Group is well-positioned to capitalize on the increasing demand for efficient healthcare solutions. They are seen as a key player.
Bear Case
- Limited information available in English makes it difficult to fully assess the company's prospects. It's like trying to navigate without a map.
- The community's bullishness might be overlooking potential risks or challenges specific to CSAM Health Group. Sometimes enthusiasm blinds you.
- Market perception of smaller healthcare tech companies can be volatile. There's a risk of being overshadowed by larger players in the space.
- Some community members express concern about the company's ability to scale its operations effectively. Execution is everything, and doubts exist.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CSAMF Latest News
No recent news available for CSAMF.
CSAMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSAMF.
Price Targets
Wall Street price target analysis for CSAMF.
CSAMF MoonshotScore
What does this score mean?
The MoonshotScore rates CSAMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sverre Flatby
CEO
Sverre Flatby serves as the CEO of CSAM Health Group AS, leading a team of 268 employees. His background includes extensive experience in the technology and healthcare sectors. Prior to joining CSAM, Flatby held various leadership positions in companies focused on software development and IT services. He has a strong track record of driving growth and innovation in technology-driven organizations. Flatby's expertise lies in strategic planning, business development, and operational management.
Track Record: Under Sverre Flatby's leadership, CSAM Health Group AS has focused on expanding its e-health solutions and strengthening its market position in specialized areas like radiology and maternity care. Key achievements include the development of new integrated systems and the expansion of the company's international presence. Flatby has also overseen efforts to ensure compliance with healthcare regulations and standards, building trust with customers and partners.
CSAMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CSAMF may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries higher risk due to the lack of regulatory oversight and transparency compared to exchanges like NYSE or NASDAQ. These companies often have very low trading volume.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the difficulty of assessing the company's financial health.
- Low Liquidity: Low trading volume and wide bid-ask spreads can make it challenging to buy or sell shares.
- Price Volatility: The stock may be subject to significant price fluctuations due to limited trading activity.
- Regulatory Oversight: Reduced regulatory oversight compared to major exchanges increases the risk of fraud or mismanagement.
- Delisting Risk: The company may face the risk of being delisted from the OTC market if it fails to meet certain requirements.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Check for any legal or regulatory issues involving the company.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- The company has been in operation since 1999.
- CSAM has a diverse product portfolio of e-health solutions.
- The company serves a variety of customers, including hospitals and clinics.
- CSAM has a team of 268 employees.
- The company has a gross margin of 74.5%.
CSAMF Healthcare Stock FAQ
What does CSAM Health Group AS do?
CSAM Health Group AS provides specialized e-health solutions, focusing on radiology, maternity care, and emergency response systems. The company offers a range of software and services, including systems for teleradiology, secure patient data transfer, and emergency medical information management. CSAM's solutions are designed to improve healthcare efficiency, enhance patient outcomes, and support healthcare providers in delivering high-quality care. The company primarily serves hospitals, clinics, and government healthcare organizations in Norway and internationally.
What are the main risks for CSAMF?
The main risks for CSAMF include competition from larger healthcare IT providers, changes in healthcare regulations, economic downturns affecting healthcare spending, and cybersecurity threats. As an OTC-listed stock, CSAMF also faces risks related to limited financial disclosure, low liquidity, and price volatility. Investors should carefully consider these risks and conduct thorough due diligence before investing in CSAMF. The company's dependence on specific niche markets, such as radiology and maternity care, also makes it vulnerable to changes in those markets.
What are the key factors to evaluate for CSAMF?
CSAM Health Group AS (CSAMF) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does CSAMF data refresh on this page?
CSAMF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CSAMF's recent stock price performance?
CSAM Health Group AS (CSAMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in niche areas like radiology and maternity care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSAMF overvalued or undervalued right now?
Valuing CSAM Health Group AS (CSAMF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CSAMF?
Before investing in CSAM Health Group AS (CSAMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CSAMF to a portfolio?
Key strength of CSAM Health Group AS (CSAMF): Specialized expertise in niche areas like radiology and maternity care. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC market data may have limited accuracy and reliability.
- AI analysis is pending and may provide additional insights.